Clinical Trials Logo

Clinical Trial Summary

In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection (AR), donor specific antibodies (DSA), and graft failure. Envarsus Extended-Release (XR)® (ENV) is a novel extended-release formulation of tacrolimus with a favorable pharmacokinetic profile, even in the setting of CYP3A5*1 allele (rapid metabolizers). The investigator will evaluate the safety and efficacy of early dose escalation with ENV in AA recipients. The study hypothesis is that higher tacrolimus target concentrations may be achieved without typical dose-limiting toxicities, and this may ultimately result in lower incidence of early AR, DSA, and graft loss.


Clinical Trial Description

Phase 4 (post-marketing) De novo African American living or deceased donor renal transplant recipients 18 to 65 years of age Number of subjects to be enrolled: 60 All patients will receive standard induction immunosuppression according to institution protocol. Within one week of transplantation, all patients will be converted from immediate-release tacrolimus (TAC) to extended-release tacrolimus (ENV) at 20% reduction in total daily dosage. Patients will be randomized to low-, moderate-, or high-intensity ENV groups, stratified by peak panel reactive antibody (pPRA) greater than or equal to 75%. Target tacrolimus trough concentrations for the first month post-transplant will be 8-10 ng/mL in low-intensity group, 10-12 ng/mL in moderate-intensity group, and 12-14 ng/mL in high-intensity group; likewise from month 1-3 post-transplant, target trough concentrations will be 6-8 ng/mL, 8-10 ng/mL, and 10-12 ng/mL, respectively. Subjects experiencing dose-limiting adverse events (AEs) will be de-escalated as warranted. Following month 3, all patients will be maintained on ENV at target tacrolimus trough concentrations according to institution protocol. Additional maintenance immunosuppression will consist of mycophenolate mofetil (MMF) at a goal dose of 2000 mg daily along with an oral prednisone taper to 5-10 mg daily by the end of month 1. All patients will be followed for 6 months post-transplant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04665310
Study type Interventional
Source The Methodist Hospital System
Contact
Status Withdrawn
Phase Phase 4
Start date September 1, 2018
Completion date October 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT01592253 - Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient N/A
Completed NCT01496703 - Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients N/A
Completed NCT00943228 - Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation Phase 4
Recruiting NCT05084768 - Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Recruiting NCT01513707 - The Effects of Pre-transplant Dialysis Modality on Post-transplant Events N/A
Not yet recruiting NCT02558452 - European Transplant Registry of Senior Renal Transplant Recipients on Advagraf N/A
Not yet recruiting NCT05799716 - Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections Phase 4